Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00639 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Jianwei Wei und 11 weiteren Autor:innen. Beteiligte Einrichtung: Balance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China. Hauptthemen laut MEDLINE: Histone-Lysine N-Methyltransferase. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Science and Technology Planning Project of Guangdong Province, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Program of Shanghai Subject Chief Scientist.
Abstract (Originalsprache)
The histone lysine methyltransferase NSD2 has been recognized as an attractive target for cancer treatment, due to the functional implication of its dysregulation in the initiation and progression of many cancers. Although considerable efforts have been made to develop NSD2 small-molecule inhibitors, highly potent and selective ones are still rarely available till now. Here, we report the discovery of a series of novel NSD2 inhibitors via an extensive SAR exploration of the privileged quinazoline scaffold within compound 8. The most promising compound 42 showed excellent NSD2 enzymatic inhibitory activity and good antiproliferative activity in cells. In addition, it demonstrated favorable pharmacokinetic properties and significantly inhibited the tumor growth in a RS411 tumor xenograft model with good safety. Taken together, compound 42 could be a promising NSD2 inhibitor and deserves further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Balance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
- Lingang Laboratory, Shanghai 200031, China.
- School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.
- State Key Laboratory of Anti-Infective Drug Development, Guangzhou 510006, China.
- School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
ORCID-Profile: Xiao-Feng Xiong, Yuanxiang Wang
Förderung
- Science and Technology Planning Project of Guangdong Province
- Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
- Program of Shanghai Subject Chief Scientist
- Shanghai Municipal Health and Family Planning Commission
- Shanghai Municipal People's Government
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
- Guangzhou Basic and Applied Basic Research Foundation
Zitieren
APA
Wei, J., Shi, Q., Li, B., Yang, H., Liu, L., Zhou, R., Feng, Z., Yang, Z., Zhan, J., Xiong, X. F., Huang, X., & Wang, Y. (2024). Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00639
Vancouver
Wei J, Shi Q, Li B, Yang H, Liu L, Zhou R, et al. Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00639
BibTeX
@article{Wei2024,
author = {Wei, Jianwei and Shi, Qiongyu and Li, Bang and Yang, Hong and Liu, Li and Zhou, Ruilin and Feng, Zongbo and Yang, Zhenjiao and Zhan, Jinhong and Xiong, Xiao-Feng and Huang, Xun and Wang, Yuanxiang},
title = {Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00639}
}
EUVIMED